Making Progress
Against Progression

With consistent results across 5 clinical trials, OFEV (nintedanib)
is advancing the management of fibrosing ILDs.
Scroll to learn more about the clinical data, mechanism of action,
and worldwide experience of OFEV1-5

FOLLOW the PATH.
SCROLL TO SEE OUR PROGRESS

ILD, interstitial lung disease.

One Proven Therapy

Nintedanib is a multi-targeted tyrosine kinase inhibitor that inhibits key pathways involved in the pathogenesis of ILDs1,6,7

MOA, mechanism of action.

OFEV can benefit patients with fibrosing
ILDs from different etiologies1,4

INDICATION
IPF

OFEV (nintedanib) was first approved for the treatment of IPF—the prototypical chronic fibrosing ILD1,11

INDICATION
SSc-ILD

OFEV is the first antifibrotic therapy FDA-approved to slow the rate of decline in pulmonary function in patients with SSc-ILD1,12

INDICATION
Chronic Fibrosing ILDs with a Progressive Phenotype

OFEV is the only FDA-approved therapy for the treatment of chronic fibrosing-ILDs with a progressive phenotype1,13

OFEV can be used in patients who have an ILD that
IS progressive in nature and fibrosing in type1,14

FDA, Food and Drug Administration; IPF, idiopathic pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

OFEV has consistent results across 5 clinical trials

INPULSIS®-1: -115 mL/year for OFEV (nintedanib) (n=309) compared with -240 mL/year for placebo (n=204); P<.001, 95% CI=78, 173.

INPULSIS®-2: -114 mL/year for OFEV (n=329) compared with -207 mL/year for placebo (n=219); P<.001, 95% CI=45, 143.

TOMORROW: -60 mL/year for OFEV (n=84) compared with -191 mL/year for placebo (n=83); P=.01, 95% CI=27, 235.

INBUILD®: -81 mL/year for OFEV (n=331)compared with -188 mL/year for placebo (n=331); P<.001, 95% CI=65, 148.

SENSCIS®: -52 mL/year for OFEV (n=287)compared with -93 mL/year for placebo (n=288); P=.04, 95% CI=3, 79.

CI, confidence interval; FVC, forced vital capacity.

Demonstrated safety and tolerability profile across 5 clinical trials1,4

  • The most common adverse reactions reported (≥5%) were diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decrease, and hypertension1
  • The most common adverse reactions were gastrointestinal in nature and generally of mild to moderate intensity1
  • No new safety concerns identified in SENSCIS® and INBUILD® compared with pivotal IPF trials1,4
  • No overall increased risk of infection compared with placebo15*

*The incidence of infections and infestations was similar in the OFEV (nintedanib) and placebo groups across trials (TOMORROW, INPULSIS®-1, and INPULSIS®-2: 56% vs 55%, respectively; INBUILD®: 53% vs 56%, respectively; and SENSCIS®: 63% vs 64%, respectively.)15

Support for your patients

Experience adds up with OFEV1